*001728983
*00520160622155427.0
*007ta
*008120131s2005    no#           000 u eng
*00901051cam a2200265 c 4500
*015  $a1109604$2nbf
*019  $bl
*035  $a(EXLNZ-47BIBSYS_NETWORK)991022530724702201
*035  $a(NO-LaBS)13893912(bibid)
*035  $a(NO-TrBIB)102253072
*035  $a102253072-47bibsys_network
*040  $aNO-OsNB$bnob$ekatreg
*042  $anorbibl
*044  $cno
*1001 $aBjorvatn, Afsaneh$0(NO-TrBIB)90805189$_29683500
*24510$aFondaparinux sodium compared with enoxaparin sodium :$ba cost-effectiveness analysis$cby Afsane Bjorvatn, Frode Kristiansen
*260  $aBergen$bInstitute for Research in Economics and Business Administration$c2005
*300  $aS. [121]-130$bfig.
*4901 $aReprint / Institute for Research in Economics and Business Administration$vno. 15/05
*500  $aSærtrykk av: Am J cardiovasc drugs, 5(2005)no. 2
*7001 $aKristiansen, Frode$0(NO-TrBIB)90235761$_91702400
*830 0$aSærtrykk (Samfunns- og næringslivsforskning : trykt utg.)$x1503-612x$vno. 15/05$w990227523664702201$_14294600
*901  $a90
*913  $aNorbok$bNB
*999  $aoai:nb.bibsys.no:991022530724702202$b2021-11-14T20:45:10Z$z991022530724702202
^